Navigation Links
HeartWare International Announces Planned Departure of Chief Financial Officer
Date:10/27/2011

160;HeartWare will host a conference call on Friday, October 28, 2011 at 8:00 a.m. U.S. Eastern Daylight Time (11:00 p.m. Australian Eastern Daylight Time, Friday, October 28, 2011) to discuss the Company's financial results, highlights from the quarter and business outlook.

The call may be accessed by dialing 1-877-941-2068 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9712.  A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Third Quarter 2011 Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
2. HeartWare Announces Presentation of Clinical Data at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon
3. HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
4. HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
5. HeartWare to Present at the Canaccord Genuity 31st Annual Growth Conference
6. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
7. HeartWare to Report Financial Results for Second Quarter of 2011
8. HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
9. HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
10. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
11. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 WHEN: ... EDTLOCATION: Online, complimentary registration available at: ... Leader Archana Vidyasekar and Visionary Innovation Research ... WiFi-like wireless electricity, self-assembling materials, nanobots and ... technologies which will transform our lives in ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... Mass. and SYDNEY, July 27, 2011 HeartWare International, Inc. ... second quarter and six months ended June 30, 2011, after ... 4, 2011. A conference call with management is ... August 4, 2011 (being 7:00 am Australian Eastern Standard Time, ...
... July 27, 2011 Varian Medical Systems (NYSE: ... of $0.83 per diluted share in the third quarter of ... year-ago quarter.  Revenues for the quarter were $649 million, up ... on a constant currency basis.  Order backlog at the end ...
Cached Medicine Technology:HeartWare to Report Financial Results for Second Quarter of 2011 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 7
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Two sisters in high ... damage. Ilina and Medha Krishen use electronic stethoscopes, ... of trouble in breathing patterns or heartbeats. Ilina, ... Michigan, wanted to find a way to detect early ... Using an electronic stethoscope, Ilina recorded one breath cycle ...
(Date:10/22/2014)... By Dennis Thompson ... -- U.S. health officials on Monday officially tightened guidelines for ... with no skin exposure and use of a respirator at ... Prevention decided to issue the tougher rules after two Dallas ... diagnosed in the United States, Liberian national Thomas Eric Duncan. ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... -- The growing number of people with Alzheimer,s disease in ... a responsibility that health experts warn can pose risks to ... to protect their health, says Rebecca Axline, a clinical social ... To keep stress in check, for instance, she emphasizes the ...
... HealthDay Reporter , WEDNESDAY, April 27 (HealthDay News) -- ... sugar control, often sending people with type 2 diabetes ... that happens. Now, a new study provides some ... decline dramatically in those who have the bypass surgery, ...
... brainy bookworms unprepared for the rough and tumble of post-graduation ... tend to fade away quickly when injected into cancer patients. ... can cause such cells to survive in patients, bloodstreams for ... of other, highly toxic treatments, a new study shows. ...
... Researchers in New York City say they are the first ... cells. A team at Albert Einstein College of Medicine ... gene transcription in living yeast cells, they say. Transcription occurs ... messenger RNA (mRNA) that then make the protein coded by ...
... , WEDNESDAY, April 27 (HealthDay News) -- An ... than earlier medications will be reviewed Thursday by a panel ... Telaprevir, made by Vertex Pharmaceuticals of Cambridge, Mass., would be ... levels of the virus, which can cause severe liver damage, ...
... (ASTRO) has developed a guideline for the use of ... to palliate thoracic symptoms caused by advanced lung cancer. ... Oncology , an official journal of ASTRO. Many patients ... treat symptoms related to cancer, such as cough, shortness ...
Cached Medicine News:Health News:Alzheimer's Caregivers Need Care, Too 2Health News:New Clues to How Gastric Bypass Surgery Combats Diabetes 2Health News:New Clues to How Gastric Bypass Surgery Combats Diabetes 3Health News:New technique extends cancer-fighting cells' potency in melanoma patients 2Health News:New technique extends cancer-fighting cells' potency in melanoma patients 3Health News:New technique extends cancer-fighting cells' potency in melanoma patients 4Health News:Researchers Describe Gene Activity in Living Cells 2Health News:Novel Hepatitis C Drug Holds Promise: FDA 2Health News:ASTRO publishes evidence-based guideline for thoracic radiotherapy 2
... helps protect you against needlestick injury. Its ... exposure to a contaminated needle, provides easy ... for use in high-risk environments. The one-handed ... for activation of the safety mechanism while ...
... The Omni-Flex System provides the ... in the middle of surgery ... on the incision. The system ... be stable for large patients ...
... The genuine BOOKWALTER™ Retractor System ... fixed" retractor design available. Its wide ... surgical specialites with a versatile system ... field. Individual BOOKWALTER™ Kits are available ...
... the Alexis Wound Retractor provides circumferential ... contamination. For open surgery, the Alexis ... the incision size. For laparoscopic surgery, ... offering retraction and protection when an ...
Medicine Products: